Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated April 28, 2026, reports a significant regulatory milestone for its investigational drug, bepirovirsen. The announcement concerns the treatment of chronic hepatitis B (CHB), a condition affecting over 250 million people globally. The filing details the acceptance of a New Drug Application (NDA) by the US Food and Drug Administration (FDA).
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This document is a current report focused exclusively on regulatory developments and clinical trial outcomes rather than financial performance.
Material Changes and Regulatory Status
- FDA Acceptance: The FDA has accepted the NDA for bepirovirsen for priority review.
- Designations: Bepirovirsen has been granted Breakthrough Therapy Designation (BTD) in addition to its existing Fast Track Designation.
- Clinical Evidence: The application is supported by Phase III B-Well 1 and B-Well 2 trials, which demonstrated statistically significant and clinically meaningful functional cure rates compared to standard of care alone.
- Safety Profile: The drug demonstrated an acceptable safety and tolerability profile consistent with previous studies.
Guidance, Outlook, and Risks
Timeline: The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 26, 2026, for the decision on the NDA.
Management Commentary: GSK highlights that current standard of care often requires lifelong therapy with low functional cure rates (typically around 1%). Bepirovirsen, a triple-action antisense oligonucleotide, aims to allow the immune system to regain control of the virus, potentially reducing the risk of liver cancer.
Risks and Contingencies: The filing includes a cautionary statement regarding forward-looking statements. Actual results may differ materially due to risks described in GSK's Annual Report on Form 20-F for 2025. The drug is currently not approved anywhere in the world.
Key Facts for Investor Verification
- Verify the specific functional cure rates and statistical significance from the B-Well 1 and B-Well 2 trials when data is presented at the European Association for the Study of Liver Congress (EASL) in 2026.
- Monitor the FDA decision status leading up to the PDUFA date of October 26, 2026.
- Review the "Risk Factors" section in GSK's 2025 Form 20-F for detailed uncertainties regarding regulatory approval and commercialization.
- Confirm the commercial partnership terms with Ionis Pharmaceuticals, from whom GSK licensed bepirovirsen.